SCHEMBL2635649

SCHEMBL2635649

Cc1c2c(c3ccccc3c1O)OC(C)(CCCC(C)CCCC(C)CCCC(C)C)C=C2

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TTPA P49638 2/20 0.43
GSTP1 P09211 1/20 0.43
USP2 O75604 1/20 0.43
THRB P10828 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PNLIP P16233 1/20 0.36
AKT1 P31749 4/20 0.35
NR1I2 O75469 1/20 0.35
PDPK1 O15530 1/20 0.35
PHLPP1 O60346 1/20 0.35
ILK Q13418 1/20 0.35
PDE4A P27815 1/20 0.35
PDE3A Q14432 1/20 0.35
GSTO1 P78417 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29305285 0.92 MAPT (0.35) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL21929589 0.85 LMNA (0.55) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL21929591 0.85 LMNA (0.55) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL21931412 0.85 LMNA (0.55) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL9285268 0.85 LMNA (0.55) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL21131789 0.85 LMNA (0.55) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL21931411 0.85 LMNA (0.55) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL21754694 0.79 LMNA (0.48) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL20646344 0.78 LMNA (0.48) LMNAMAPTMEN1KMT2ATTPA
SCHEMBL21875424 0.77 LMNA (0.43) LMNAMAPTMEN1KMT2ATTPA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217941-A1 RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASIC CATALYST DSM IP ASSETS B.V. (NL) 2024-07-04 US disclosed
US-20240217941-A1 RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASIC CATALYST DSM IP ASSETS B.V. (NL) 2024-07-04 US disclosed
EP-2558084-A2 COMBINATION OF VITAMIN K AND NICOTINAMIDE Fresenius Medical Care Deutschland GmbH (DE) 2013-02-20 EP disclosed
WO-2011141113-A2 COMBINATION OF VITAMIN K AND NICOTINAMIDE FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217941-A1 RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASIC CATALYST SQLE, VKORC1, TTPA LMNA 1226/4885MAPT 4633/4885MEN1 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.